Financial Performance - Revenue for the six months ended December 31, 2022, was HK$365,102,000, representing a 2% increase from HK$358,210,000 in 2021[12]. - EBITDA for the same period was HK$101,820,000, reflecting a 3% increase from HK$98,615,000 in 2021[12]. - Profit attributable to owners from continuing operations decreased by 5% to HK$42,469,000 compared to HK$44,661,000 in the previous year[12]. - Total profit decreased by 8% to HK$42,469,000 from HK$46,327,000 in 2021[12]. - Basic and diluted earnings per share decreased by 10% to 5.425 HK cents from 6.053 HK cents[12]. - Total consolidated revenue from continuing operations increased by 1.9% from HK$358.2 million in 1HFY2022 to HK$365.1 million in 1HFY2023[110]. - For the six months ended December 31, 2022, total revenue decreased by 10.6% to HK$576.4 million compared to HK$645.0 million in the same period of 2021[136]. Dividends and Shareholder Returns - Interim dividend per share increased by 13% to 1.70 HK cents from 1.50 HK cents[12]. - The Board declared an interim dividend of HK1.70 cents per ordinary share for the six months ended 31 December 2022, an increase from HK1.50 cents in FY2022[193]. Cash and Assets - Cash and pledged deposits increased by 20% to HK$286,902,000 from HK$238,120,000[12]. - As of December 31, 2022, the Group had cash and cash equivalents of HK$284.5 million and no bank borrowings or outstanding loans[151]. - The Group's gearing ratio was zero as of December 31, 2022, indicating no net debt[153]. - As of December 31, 2022, the Group's right-of-use assets amounted to HK$137.1 million, a slight increase from HK$136.0 million as of June 30, 2022[138]. - Investments at fair value through other comprehensive income increased to HK$37.5 million, while financial assets at amortised cost decreased to HK$6.3 million as of December 31, 2022[144]. Operational Developments - The company launched its first personalized healthcare scheme in October 2022, enhancing its corporate healthcare solutions[20]. - Two new imaging centers equipped with advanced technology such as PET-CT and MRI are set to begin operations this year[19]. - The company established a new large medical ecosystem in Central, enhancing one-stop healthcare services for patients[22]. - The UMP Healthcare Innov Centre was established to showcase advanced medical application technologies and explore AI in diagnosis and care processes[25]. - The Group's extensive clinical chains support both corporate healthcare solutions and walk-in users, with demand for specialist services remaining stable despite pandemic impacts[60]. Market and Strategic Initiatives - The company aims to create a sustainable healthcare system that is accessible, inclusive, and affordable while ensuring profitability[31]. - The company remains cautiously optimistic about market recovery as cross-border travel resumes, serving the region's 80 million citizens[29]. - Strategic collaborations with private hospitals and healthcare groups are being pursued to enhance service delivery and operational efficiency[30]. - The demand for body health check services continued to rise due to increased healthcare awareness and an aging population[64]. - The Group aims to consolidate strengths and increase overall market share and competitiveness in the healthcare sector[96]. Employee and Operational Costs - Employee benefit expenses increased by 7.5% from HK$83.9 million in 1HFY2022 to HK$90.2 million in 1HFY2023, aligning with the company's talent strategy for business growth[123]. - Professional services expenses decreased by 3.4% from HK$127.3 million in 1HFY2022 to HK$123.0 million in 1HFY2023, reflecting a reduction in service costs from healthcare professionals[121]. - Initial operating expenses from new integrated services medical centres at OCC contributed to the decline in operating profit for clinical healthcare services[59]. Governance and Leadership - Dr. SUN Yiu Kwong retired as CEO effective January 1, 2023, while remaining as Chairman and an executive Director[199]. - The Company has complied with the Corporate Governance Code by separating the roles of Chairman and CEO[199]. - The Board will periodically review the corporate governance structure and practices[200].
联合医务(00722) - 2023 - 中期财报